- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02542371
Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
Descripción general del estudio
Descripción detallada
Detailed Description:
Patients with HIV have been shown to have increased atherosclerotic risk compared to age-matched controls, and this risk is thought to be related to increased systemic immune activation. Specifically, systemic immune activation may contribute to destabilizing coronary atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using single photon emission computed tomography, applied initially to a group of HIV-infected patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis will prompt subsequent study of three comparison groups, as above.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
HIV infected subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- known active opportunistic infection requiring ongoing medical therapy (not including Hepatitis B/C)
- CD4 count < 50 cells/mm3
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV infected subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of clean aorta/ coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV infected subjects with known subclinical atherosclerosis
HIV negative subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV negative subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of clean aorta/coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV negative subjects with known subclinical atherosclerosis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Control de caso
- Perspectivas temporales: Transversal
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
HIV infected with known subclinical atherosclerosis
|
|
|
HIV infected without known subclinical atherosclerosis
|
|
|
Non-HIV infected with known subclinical atherosclerosis
|
|
|
Non-HIV infected without known subclinical atherosclerosis
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Aortic plaque burden and morphology on CCTA in HIV Patients
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Imaging assessments in the coronary vasculature in HIV patients
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta
Periodo de tiempo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Steven Grinspoon, M.D., Massachusetts General Hospital
Publicaciones y enlaces útiles
Publicaciones Generales
- Toribio M, Wilks MQ, Hedgire S, Lu MT, Cetlin M, Wang M, Alhallak I, Durbin CG, White KS, Wallis Z, Schnittman SR, Stanley TL, El-Fakhri G, Lee H, Autissier P, Zanni MV, Williams KC, Grinspoon SK. Increased Macrophage-Specific Arterial Infiltration Relates to Noncalcified Plaque and Systemic Immune Activation in People With Human Immunodeficiency Virus. J Infect Dis. 2022 Nov 11;226(10):1823-1833. doi: 10.1093/infdis/jiac301.
- Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, Autissier P, Foldyna B, Stone L, Martin A, Cope F, Abbruzzese B, Brady T, Hoffmann U, Williams KC, El-Fakhri G, Grinspoon SK. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 Apr 15;215(8):1264-1269. doi: 10.1093/infdis/jix095.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2014P001832
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .